Please note: In October and November 2010, the MHRA moved from its Market Towers address to a new location on Buckingham Palace Road. Please go to the contact us section of the website for updated contact details.
A list of letters sent to healthcare professionals in March 2007, to inform of new safety information and advice.
| Date issued | Product | Safety information |
|---|---|---|
| Week beginning 05/03/2007 | Baraclude (entecavir) | Risk of HIV resistance in patients co-infected with HIV and hepatitis B virus who are not receiving highly active anti-retroviral therapy (HAART) |
| 06/03/2007 | Dotarem (gadoteric acid) | Risk of nephrogenic systemic fibrosis Further information is available in the following section: Nephrogenic Systemic Fibrosis (NSF) and gadolinium-containing MRI contrast agents |
| 26/03/2007 | InductOs (dibotermin alfa) | Reminder of correct dose and placement of product during anterior spine fusion surgery; risk of fluid collection during unapproved use in posterior lumbar spine surgery |
| 03/2007 | Rosiglitazone-containing products (Avandia, Avandamet, and Avaglim) | Risk of fractures in feet, hands, and upper arms in women |
| 07/03/2007 | Zyvox (linezolid) | Restriction of indication in complicated skin and soft-tissue infections |
